SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Coomans Marijke B.)
 

Sökning: WFRF:(Coomans Marijke B.) > (2022) > Factors associated ...

  • Coomans, MarijkeLeiden Univ, Netherlands (författare)

Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2022-04-11
  • Oxford University Press,2022
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-185298
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-185298URI
  • https://doi.org/10.1093/neuonc/noac097DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group [RP 1515]
  • Background Maintenance of functioning and well-being during the progression-free survival (PFS) period is important for glioma patients. This study aimed to determine whether health-related quality of life (HRQoL) can be maintained during progression-free time, and factors associated with HRQoL deterioration in this period. Methods We included longitudinal HRQoL data from previously published clinical trials in glioma. The percentage of patients with stable HRQoL until progression was determined per scale and at the individual patient level (i.e. considering all scales simultaneously). We assessed time to a clinically relevant deterioration in HRQoL, expressed in deterioration-free survival and time-to-deterioration (the first including progression as an event). We also determined the association between sociodemographic and clinical factors and HRQoL deterioration in the progression-free period. Results Five thousand five hundred and thirty-nine patients with at least baseline HRQoL scores had a median time from randomization to progression of 7.6 months. Between 9-29% of the patients deteriorated before disease progression on the evaluated HRQoL scales. When considering all scales simultaneously, 47% of patients deteriorated on >= 1 scale. Median deterioration-free survival period ranged between 3.8-5.4 months, and median time-to-deterioration between 8.2-11.9 months. For most scales, only poor performance status was independently associated with clinically relevant HRQoL deterioration in the progression-free period. Conclusions HRQoL was maintained in only 53% of patients in their progression-free period, and treatment was not independently associated with this deterioration in HRQoL. Routine monitoring of the patients functioning and well-being during the entire disease course is therefore important, so that interventions can be initiated when problems are signaled.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Dirven, LindaLeiden Univ, Netherlands; Haaglanden Med Ctr, Netherlands (författare)
  • Aaronson, NeilNetherlands Canc Inst, Netherlands (författare)
  • Baumert, Brigitta G.Kantonsspital Graubunden, Switzerland; Maastricht Univ, Netherlands; Maastricht Univ, Netherlands (författare)
  • van den Bent, MartinErasmus MC Canc Inst, Netherlands (författare)
  • Bottomley, AndrewEuropean Org Res Treatment Canc, Belgium (författare)
  • Brandes, Alba A.Azienda USL IRCCS Inst Neurol Sci, Italy (författare)
  • Chinot, OlivierAix Marseille Univ, France (författare)
  • Coens, CorneelEuropean Org Res Treatment Canc, Belgium (författare)
  • Gorlia, ThierryEuropean Org Res & Treatment Canc Headquarters, Belgium (författare)
  • Herrlinger, UlrichUniv Bonn, Germany (författare)
  • Keime-Guibert, FlorenceGrp Hop Pitie Salpetriere, France (författare)
  • Malmström, AnnikaLinköpings universitet,Avdelningen för cellbiologi,Medicinska fakulteten,Region Östergötland, Närvårdskliniken(Swepub:liu)annma14 (författare)
  • Martinelli, FrancescaEuropean Org Res Treatment Canc, Belgium (författare)
  • Stupp, RogerNorthwestern Univ, IL 60611 USA (författare)
  • Talacchi, AndreaAzienda Osped San Giovanni Addolorata, Italy (författare)
  • Weller, MichaelUniv Hosp, Switzerland; Univ Zurich, Switzerland (författare)
  • Wick, WolfgangUniv Hosp Heidelberg, Germany; Univ Hosp Heidelberg, Germany; German Canc Res Ctr, Germany (författare)
  • Reijneveld, Jaap C.Univ Amsterdam, Netherlands; Univ Amsterdam, Netherlands (författare)
  • Taphoorn, Martin J. B.Leiden Univ, Netherlands; Haaglanden Med Ctr, Netherlands (författare)
  • Leiden Univ, NetherlandsLeiden Univ, Netherlands; Haaglanden Med Ctr, Netherlands (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Neuro-Oncology: Oxford University Press24:12, s. 2159-21691522-85171523-5866

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy